Glucoerb + epavin
1 paper4 findings
- 1 lab in 1 country
- Human trial1
Outcomes
2Endothelial function
upin humans1+19%
1 study
Endothelial function
upin humans1+19%
Glucoerb + epavin improves endothelial function in humans (+19%).
“while endothelial function improved (+19%, p = 0.017).”
HumansOverweight or obesity; combined supplementation alongside nutritional counselling and physical activity recommendations3 monthsn = 50
Journal of clinical medicine23 Sep 2026
Fatty liver index
downin humans1−17%
1 study
Fatty liver index
downin humans1−17%
Glucoerb + epavin decreases fatty liver index in humans (-17%).
“Fatty Liver Index decreased across all groups (Glucoerb® -14%, Epavin® -19%, combination -17%).”
HumansOverweight or obesity; alongside nutritional counselling and physical activity recommendations3 monthsn = 50
Journal of clinical medicine23 Sep 2026
Associations
2HOMA-IR
downin humans1−32%
1 study
HOMA-IR
downin humans1−32%
Glucoerb + epavin is associated with HOMA-IR in humans (-32%).
“Combined supplementation was associated with reductions in body weight (-6%) and HOMA-IR (-32%)”
HumansOverweight or obesity; alongside nutritional counselling and physical activity recommendations3 monthsn = 50
Journal of clinical medicine23 Sep 2026
Body weight
downin humans1−6%
1 study
Body weight
downin humans1−6%
Glucoerb + epavin is associated with body weight in humans (-6%).
“Combined supplementation was associated with reductions in body weight (-6%) and HOMA-IR (-32%)”
HumansOverweight or obesity; alongside nutritional counselling and physical activity recommendations3 monthsn = 50
Journal of clinical medicine23 Sep 2026